real-time news and commentary for investors
Wednesday, Oct 9
Acura Pharma +12% AH on Oxecta patent litigation settlement
- Acura Pharmaceuticals (ACUR) +11.8% AH after announcing a settlement of patent litigation with Par Pharmaceutical (PRX) and Impax Labs (IPXL) over the pain drug Oxecta.
- According to the terms, PRX may launch its generic Oxecta product in the U.S., through the grant of a non-exclusive license which requires it to pay ACUR royalties in the range of 10%-15% of PRX's net profits from the sale.
- IPXL may launch its generic Oxecta product in the U.S. through the grant of a non-exclusive, royalty-free license.